DRUG SURVIVAL RATES AND COST OF BIOLOGICAL AGENTS FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE BALEARIC ISLANDS (SPAIN)

Author(s)

Ventayol P
Hospital Son Espases, Palma de Mallorca, Spain

OBJECTIVES There are few studies combining dose regimen in routine clinical practice, drug survival rates and costs of biological agents for the treatment of naïve patients with moderate-to-severe psoriasis in the clinical practice. To assess the dose regimen in routine clinical practice, drug survival rate (persistence rate) and efficiency (cost per persistence) for etanercept (ETN), adalimumab (ADA) and ustekinumab (UST) in a real practice clinical setting. METHODS A retrospective study on psoriasis patients aged ≥18 years, naïve to a biological agent and a minimum of 6 months of treatment was performed in 5 public health system hospitals in the Balearic Islands (Spain) for the period from January 1st

Conference/Value in Health Info

2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands

Value in Health, Vol. 17, No. 7 (November 2014)

Code

PSS37

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×